Consensus approaches to best practice management of gastrointestinal stromal tumors

Zalcberg, John; Desai, Jayesh; Mann, Bruce; Fox, Stephen B.; Goldstein, David; McArthur, Grant A.; Clark, Matthew A.; Yip, Desmond

doi:10.1111/j.1743-7563.2008.00218.x

Cited by 3 publications

(5 citation statements)

References 44 publications

(140 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently published data concerning some of these questions are discussed from an Australian perspective. This paper updates the Consensus approaches to best practice management of gastrointestinal stromal tumors published in this journal in 2008 …”

Section: Introductionmentioning

confidence: 90%

“…The available evidence indicates that adjuvant imatinib is most relevant to patients at a high risk of recurrence . In Australia, high risk is defined for reimbursement purposes as primary GIST >5 cm with a MI >5/50 HPF; or >10 cm with any mitotic rate; or with a MI >10/50 HPF as defined in the Australian and New Zealand consensus approach to best practice management . Most treatment guidelines currently recommend 3 years of adjuvant imatinib therapy in these high‐risk patients…”

Section: Imatinib In Primary Gistmentioning

confidence: 99%

“…The advent of imatinib, a tyrosine kinase inhibitor (TKI) that blocks signaling via KIT and PDGFRA, has revolutionized therapy, initially for patients with metastatic or advanced disease and more recently as adjuvant therapy for patients with primary GIST that has a high risk of recurrence . In both settings, improved progression‐free survival (PFS) and overall survival (OS) have been demonstrated . In parallel with the availability of effective treatment, there have also been significant developments in the diagnosis and staging of the disease.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Controversies in the management of gastrointestinal stromal tumors

Yip

Zalcberg

Ackland

et al. 2014

Asia-Pac J Clncl Oncology

Self Cite

View full text Add to dashboard Cite

Major advances in the medical treatment of gastrointestinal tumors (GISTs) have improved survival for both patients with advanced disease and those diagnosed with high-risk primary tumors. The Consensus approaches to best practice management of gastrointestinal stromal tumors, published in this journal in 2008, provided guidance for the management of GIST to both clinicians and regulatory authorities. Since then, clinical trials have demonstrated the benefit of adjuvant imatinib in high-risk patients, and mature data from advanced GIST studies suggest that a small but significant proportion of patients with advanced disease can achieve long-term benefit with ongoing imatinib treatment. Other evolving management strategies include the controversial use of palliative or debulking surgery to improve outcomes in advanced GIST and the development of promising new multikinase inhibitors, such as regorafenib, which has established benefit in the third-line setting. This review provides an update of recent developments in GIST management and discusses new controversies that these advances have generated.

show abstract

Section: Introductionmentioning

confidence: 90%

Section: Imatinib In Primary Gistmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Controversies in the management of gastrointestinal stromal tumors

Yip

Zalcberg

Ackland

et al. 2014

Asia-Pac J Clncl Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the western countries, histopathologic criteria and molecular pathologic mechanism of GIST have recently standardized and the guidelines for this entity have been published by the National Comprehensive Cancer Network (NCCN) ( 1 ) and the European Society of Medical Oncology (ESMO) ( 2 ). And in Japan and Australia, the guidelines appropriate for clinical practice in each country have been also published ( 3 , 4 )…”

Section: Introductionmentioning

confidence: 99%

Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea

et al. 2010

View full text Add to dashboard Cite

Despite the rarity in incidence and prevalence, gastrointestinal stromal tumor (GIST) has emerged as a distinct pathogenetic entity. And the clinical management of GIST has been evolving very rapidly due to the recent recognition of its oncogenic signal transduction pathway and the introduction of new molecular-targeted therapy. Successful management of GIST requires a multidisciplinary approach firmly based on accurate histopathologic diagnosis. However, there was no standardized guideline for the management of Korean GIST patients. In 2007, the Korean GIST study group (KGSG) published the first guideline for optimal diagnosis and treatment of GIST in Korea. As the second version of the guideline, we herein have updated recent clinical recommendations and reflected changes in diagnosis, surgical and medical treatments for more optimal clinical practice for GIST in Korea. We hope the guideline can be of help in enhancing the quality of diagnosis by members of the Korean associate of physicians involving in GIST patients's care and subsequently in achieving optimal efficacy of treatment.

show abstract

“…In the meantime, the lessons learned in recent rapid research on GIST need to be reviewed and consolidated, so that clinicians can provide optimal care. In this issue, several experts have collaborated to review the current evidence and optimal approach for diagnosis and management of GIST, and provided succinct guidelines for clinicians 12 . They have reviewed clinical issues extending in range from reporting of pathology, through surgical and medical management, to managing imatinib toxicity and second‐line therapy.…”

mentioning

confidence: 99%